EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Integrated Network Pharmacology and Experimental Validation Approach to Investigate the Mechanisms of Stigmasterol in the Treatment of Rheumatoid Arthritis

Wendong Xie iD, Hua Yang, Chun Guo, Rui Xie, Guoliang Yu, Yifu Li

Drug Design, Development and Therapy · 2023

DOI: 10.2147/dddt.s387570 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2023. Verfasst von Wendong Xie und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Bioscience and Biotechnology, Hunan Agricultural University, Changsha, People's Republic of China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Arthritis, Experimental, Drugs, Chinese Herbal. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints associated with systemic comorbidities. Sinomenium acutum is regarded as an effective traditional Chinese medicine (TCM) for the treatment of RA. Materials and Methods: Based on network pharmacology and Gene Expression Omnibus (GEO) database, 33 RA-related differentially-expressed genes (DEGs) targeting active compounds of Sinomenium acutum were initially screened in our investigation.

Results

Gene Ontology (GO) and Kyoto encyclopaedia of genes and genome (KEGG) analyses found the important involvement of these DEGs in osteoclast differentiation, and finally 5 core DEGs, including NCF4, NFKB1, CYBA, IL-1β and NCF1 were determined through protein-protein interaction (PPI) network. We also identified the related active component of Sinomenium acutum include Stigmasterol. Finally, in order to experimentally verify these results, a rat model of collagen-induced arthritis (CIA) was established, and subsequently treated with Stigmasterol solution.

Conclusion

Similar to the healing effect of Indomethacin, Stigmasterol was observed to reduce the levels of inflammatory factors (IL-6 and IL-1β) and osteoclast differentiation-related factors (RANKL, ACP5 and Cathepsin K), which can also reduce the arthritis index score and alleviate the degree of pathological injury of rat ankle joints. The predictions and experimental data uncover the involvement of Stigmasterol, an active component of Sinomenium acutum, in regulation of osteoclast differentiation, exerting great medicinal potential in the treatment of RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidArthritis, ExperimentalDrugs, Chinese HerbalRatsAnimalsStigmasterolNetwork PharmacologyProtein Interaction MapsMedicine, Chinese Traditional

Stichwörter der Autor:innen

Sinomenium acutumnetwork pharmacologyosteoclastsrheumatoid arthritisstigmasterol

Substanzen

StigmasterolDrugs, Chinese Herbal

Autor:innen und Institutionen

  • College of Bioscience and Biotechnology, Hunan Agricultural University, Changsha, People's Republic of China.
  • Medical Innovation Experiment Center, The First Hospital of Hunan University of Traditional Chinese Medicine, Changsha, People's Republic of China.

ORCID-Profile: Wendong Xie

Zitieren

APA

Xie, W., Yang, H., Guo, C., Xie, R., Yu, G., & Li, Y. (2023). Integrated Network Pharmacology and Experimental Validation Approach to Investigate the Mechanisms of Stigmasterol in the Treatment of Rheumatoid Arthritis. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s387570

Vancouver

Xie W, Yang H, Guo C, Xie R, Yu G, Li Y. Integrated Network Pharmacology and Experimental Validation Approach to Investigate the Mechanisms of Stigmasterol in the Treatment of Rheumatoid Arthritis. Drug Design, Development and Therapy. 2023. doi:10.2147/dddt.s387570

BibTeX
@article{Xie2023,
  author = {Xie, Wendong and Yang, Hua and Guo, Chun and Xie, Rui and Yu, Guoliang and Li, Yifu},
  title = {Integrated Network Pharmacology and Experimental Validation Approach to Investigate the Mechanisms of Stigmasterol in the Treatment of Rheumatoid Arthritis},
  journal = {Drug Design, Development and Therapy},
  year = {2023},
  doi = {10.2147/dddt.s387570}
}
Kostenlos starten →